Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results